Pilot trial of bone‐targeted therapy with zoledronate, thalidomide, and interferon‐γ for metastatic renal cell carcinoma
暂无分享,去创建一个
K. Do | E. Jonasch | L. Rhines | P. Lin | A. Siefker-Radtke | L. Pagliaro | S. Tu | Sue-Hwa Lin | N. Tannir | P. Mathew | Rita F. Tibbs
[1] F. Saad,et al. Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] R. Motzer,et al. AG-013736, a multi-target tyrosine kinase receptor inhibitor, demonstrates anti-tumor activity in a Phase 2 study of cytokine-refractory, metastatic renal cell cancer (RCC) , 2005 .
[3] R. Bukowski,et al. Randomized phase III trial of the Raf kinase and VEGFR inhibitor sorafenib (BAY 43–9006) in patients with advanced renal cell carcinoma (RCC) , 2005 .
[4] M. Atkins,et al. Update on the Role of Interleukin 2 and Other Cytokines in the Treatment of Patients with Stage IV Renal Carcinoma , 2004, Clinical Cancer Research.
[5] G. Roodman. Mechanisms of bone metastasis. , 2004, Discovery medicine.
[6] S. Liou,et al. Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] A. Lipton,et al. Zoledronic acid delays the onset of skeletal‐related events and progression of skeletal disease in patients with advanced renal cell carcinoma , 2003, Cancer.
[8] Seth M Steinberg,et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. , 2003, The New England journal of medicine.
[9] P. Thall,et al. A pilot study of thalidomide in patients with progressive metastatic renal cell carcinoma , 2002, Cancer.
[10] L. Demers,et al. Biochemical markers and skeletal metastases. , 2001, Clinical orthopaedics and related research.
[11] K. Inoue,et al. Diagnostic value of bone‐turnover metabolites in the diagnosis of bone metastases in patients with lung carcinoma , 2001, Cancer.
[12] Hiroshi Takayanagi,et al. T-cell-mediated regulation of osteoclastogenesis by signalling cross-talk between RANKL and IFN-γ , 2000, Nature.
[13] P. Haslett,et al. Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha. , 1999, Journal of immunology.
[14] M. Gleave,et al. Interferon Gamma-1b Compared with Placebo in Metastatic Renal-Cell Carcinoma , 1999 .
[15] D. Lacombe,et al. Assessment of bone response to systemic therapy in an EORTC trial: preliminary experience with the use of collagen cross-link excretion , 1999, British Journal of Cancer.
[16] G. Hortobagyi,et al. Markers of bone resorption in patients treated with pamidronate. , 1998, European journal of cancer.
[17] P. Croucher,et al. The bisphosphonate incadronate (YM175) causes apoptosis of human myeloma cells in vitro by inhibiting the mevalonate pathway. , 1998, Cancer research.
[18] P. Haslett,et al. Thalidomide Costimulates Primary Human T Lymphocytes, Preferentially Inducing Proliferation, Cytokine Production, and Cytotoxic Responses in the CD8+ Subset , 1998, The Journal of experimental medicine.
[19] S. Handt,et al. Thalidomide selectively modulates the density of cell surface molecules involved in the adhesion cascade. , 1996, Immunopharmacology.
[20] C. Logothetis,et al. Phase II trial of low dose γ-interferon in metastatic renal cell carcinoma , 1994 .
[21] R. Coleman. Evaluation of bone disease in breast cancer , 1994 .
[22] O. S. Nielsen,et al. Bone metastases: pathophysiology and management policy. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] B. Mull,et al. Successful treatment of metastatic renal cell carcinoma with a biologically active dose of recombinant interferon-gamma. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] G. Giacco,et al. Osseous metastases secondary to renal cell carcinoma. , 1981, Urology.
[25] E. Kaplan,et al. Nonparametric Estimation from Incomplete Observations , 1958 .
[26] T. Eisen. Thalidomide in solid tumors: the London experience. , 2000, Oncology.
[27] A. Lichtenstein,et al. In vitro cytoreductive effects on multiple myeloma cells induced by bisphosphonates , 1998, Leukemia.
[28] Demichelis,et al. Evaluation of the , 1992, Physical review. B, Condensed matter.